TAG / FDA

A 10‑member FDA panel met amid mounting evidence that antidepressants may impair fetal brain development.

Psychiatrists push for electroshock on children—even as global bodies condemn it, courts rebuke it and victims recount the brain damage it leaves behind.

Evidence suggests drugmakers manipulated trials and government failed to respond while patients live with permanent loss of sexual function.

Purdue prepares to pay up, leaving unanswered questions about justice, accountability and how hundreds of thousands of lives might have been saved if regulators had acted sooner.

Six years after doctors petitioned for Post-SSRI Sexual Dysfunction label warnings, the FDA has done nothing. Now, victims are speaking out—before more lives are destroyed.

From cozy relationships to blockbuster approvals, a new FDA policy promises transparency after decades of industry entanglement. But is it too little, too late?

As an FDA executive, Cavazzoni handed Pfizer, her former employer, a record-setting number of approved drugs in one year. And now she’s back. There’s a reason they call it the “revolving door.”

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

The study is part of psychiatry’s broad new initiative to normalize the use of hallucinogenic drugs, despite their dangerous side effects. Why? As always, follow the money.

According to the DOJ, this is the first time a management consulting firm has been held criminally responsible for advice resulting in the commission of a crime by a client—in this case, Purdue.